Alzheimer's disease

News

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on

News

Lexeo shares dip on early data with Alzheimer's gene therapy

Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.

News

Lilly touts new Kisunla regimen that reduces side effects

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions f

News

AbbVie gets bigger in Alzheimer's R&D with Aliada takeover

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing.

News

Lilly's Alzheimer's drug gets UK nod, but no NHS funding

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NI

News

Australia joins EU in turning down Alzheimer's drug Leqembi

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy Leqembi, saying its efficacy does not outweigh its risks.

Eisai, Biogen eye 2025 approval for Leqembi autoinjector

Lexeo shares dip on early data with Alzheimer's gene therapy

Lilly touts new Kisunla regimen that reduces side effects

AbbVie gets bigger in Alzheimer's R&D with Aliada takeover

Lilly's Alzheimer's drug gets UK nod, but no NHS funding

Australia joins EU in turning down Alzheimer's drug Leqembi

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Alzheimer's disease

Editor's Picks